March 6, 2020
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE: 002399), a China-based global pharmaceutical company targeting high-mortality diseases with significant unmet medical needs, announced the appointment of Mr. Frank Sun as Executive Director and the election of Mr. Sun as the Vice Chairman of the Board. Mr. Sun will work with the Board on strategy design, enhancement and implementation, and lead the efforts in strategic investment, capital markets, and the development of Hepalink’s innovative businesses globally.
"We are thrilled to have an industry veteran such as Frank joining us,” said Mr. Li Li, Hepalink’s co-founder and Chairman. “He brings 20 years of experience in top global companies, and a broad set of expertise in the healthcare industry, investment, corporate finance and management. This is an exciting time for Hepalink, as we accelerate value realization driven by continued focus on innovation and global expansion. Frank’s leadership and expertise will be critical to helping Hepalink reach the next stage of growth."
Mr. Sun joins Hepalink from Yunfeng Capital, one of the largest China-based private equity funds, where he served as Managing Director responsible for global healthcare investment. Prior to Yunfeng, Mr. Sun worked at UBS AG, and served as Managing Director and Head of Asia Healthcare Investment Banking. Previously, he was a pharmaceutical sector equity research analyst with Morgan Stanley based in New York, and a research scientist at Bristol-Myers Squibb.
Mr. Sun graduated with distinction and received his MBA from NYU Stern School of Business. He has a Master’s degree in pharmacology from Columbia University. Mr. Sun is a director of the China Healthcare Investment 50 Forum (H50).
Founded by a group of seasoned polysaccharide-chemists with scientific insights and profound understanding of immunology, Hepalink is a leading China-based pharmaceutical company with global businesses in pharmaceutical, innovative biotech and CDMO sectors. We have built up a portfolio of both leading drugs in the anticoagulant and antithrombotic therapeutic areas and innovative drug candidates focusing on diseases with an immune system disorder axis, including oncology, autoimmune, metabolic and other areas.